FIELD: medicine.
SUBSTANCE: composite application of therapeutic preparations is combined with a laser therapy. A basic anti-inflammatory preparation is presented by methotrexate administered subcutaneously in a dose of 15mg once a week, and folic acid administered orally in a dose of 5mg a week. Movalis is additionally prescribed in the form of intramuscular injections in a dose of 15mg once a day. The laser therapy is differentiated depending on a degree of the disease, a degree of endothelial dysfunction manifestation, namely a von Willebrand factor (vWF), haemostasis system activity indices, namely activated partial thromboplastin time (APTT), prothrombin time (PTT), thrombin clotting time (TCT), antithrombin III (AT III), protein C. If observing the degree I of the disease, APTT 30.6±1.5 sec or more, PTT 19.2±0.9 sec or more, TCT 15.1±0.7 sec or more, AT III 92.8±7.6% or more, protein C 0.92±0.02 or more, vWF 108.9±9.6% or less, 6-8 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at a light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day. The degrees II and III of the disease, APTT 22.2±5.5 sec or less, PTT 12.8±1.7 sec or less, TCT 11.2±0.9 sec or less, AT III 85.4±1.1% or less, protein C 0.84±0.02 and less, vWF 133.5±2.2% or more, require performing 10 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at the light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day.
EFFECT: method enables reducing the clinical manifestations of the disease, provides higher effectiveness of the drug therapy by involving the pathological processes in the haemostasis system.
1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING PATIENTS WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2573631C2 |
METHOD OF TREATING PATIENTS WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2554232C1 |
THERAPY OF PATIENTS SUFFERING FROM ESSENTIAL HYPERTENSION | 2008 |
|
RU2364429C1 |
METHOD OF TREATING PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS | 2013 |
|
RU2556577C1 |
METHOD FOR PREVENTION OF POSTOPERATIVE THROMBOHAEMORRHAGIC COMPLICATIONS IN PATIENTS UNDERGONE HYSTEROMYOMA SURGERY WITH PREOPERATIVE COAGULOGRAM VARIATIONS TO HYPERCOAGULATION | 2013 |
|
RU2534857C1 |
METHOD OF CORRECTING HAEMOSTATIC DISORDERS IN CASE OF CHRONIC CALCULOUS CHOLECYSTITIS AT BACKGROUND OF CHRONIC HEPATITIS OR CIRRHOSIS OF LIVER | 2013 |
|
RU2526117C1 |
METHOD FOR TREATMENT OF PNEUMONIA PATIENTS | 2007 |
|
RU2347595C1 |
METHOD FOR PREDICTING CLINICAL COURSE OF RESPIRATORY ORGANS SARCOIDOSIS ON THE BACKGROUND OF GLUCOCORTICOID THERAPY | 2006 |
|
RU2319451C2 |
METHOD FOR HOMEOSTATIC DISORDER CORRECTION IN CHILDREN WITH HEPATIC HEMANGIOMAS | 2012 |
|
RU2483737C1 |
METHOD FOR ASSESSING RISK OF BLEEDING DURING AND AFTER DENTAL INTERVENTIONS IN PATIENTS TAKING ORAL ANTICOAGULANTS | 2023 |
|
RU2813439C1 |
Authors
Dates
2015-01-10—Published
2013-07-10—Filed